PESUF22	Evaluating legal obstacles to provider-assisted injection in Ontario's Supervised Consumption Services	Poster exhibition	Availability and access to harm reduction (including OST and NSP)
EPE248	A shift from onsite to online dissemination of new WHO treatment guidelines for HIV and TB through short interactive courses for health workers. Is it cost effective?	E-poster	Assessments of cost effectiveness: Provider and community perspectives
EPE249	Affordability of integrating early childhood development into PMTCT programs	E-poster	Assessments of cost effectiveness: Provider and community perspectives
EPE250	Cost'benefit analysis of investments made in Morocco since the creation of the Global Fund (2002 - 2020) for HIV control	E-poster	Assessments of cost effectiveness: Provider and community perspectives
PESUE25	Optimal treatment and prevention mix for South Africa's UTT program	Poster exhibition	Assessments of cost effectiveness: Provider and community perspectives
EPA065	Ex vivo HIV suppression in foreskin tissue after oral dosing of F/TDF and F/TAF in young African males	E-poster	ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics
EPA066	Mode of interaction of CD4-CD4i antibody hybrids to HIV-1 envelope glycoproteins	E-poster	ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics
EPA067	Small-molecule CD4-mimetic compounds expose vulnerable HIV-1 Env epitopes and contact the highly conserved aspartic acid 368	E-poster	ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics
EPA068	Metformin acts on HIV reservoirs to facilitate their recognition by the immune system	E-poster	ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics
EPA069	Dual antiretroviral loaded nanoparticles for long-acting suppressive HIV therapy	E-poster	ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics